NASDAQ:ADXS Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis $0.11 +0.08 (+231.23%) As of 03:52 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Ayala Pharmaceuticals Stock (NASDAQ:ADXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ayala Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.10▼$0.1550-Day Range$0.03▼$0.1152-Week Range$0.00▼$0.78Volume215,940 shsAverage Volume8,302 shsMarket Capitalization$4.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Read More… Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXS Stock News HeadlinesRockville's OS Therapies acquires rights to key drugs, eyes FDA approval for cancer therapyFebruary 5, 2025 | bizjournals.comOS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to PipelineJanuary 29, 2025 | businesswire.comThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.May 1, 2025 | Investors Alley (Ad)Ayala unit expands cold storage networkSeptember 4, 2024 | msn.comAyala explores minority stake sale in AC Health, sources sayAugust 1, 2024 | msn.comAyala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting ObligationsMay 9, 2024 | globenewswire.comImmunome: An Oncology Powerhouse In The MakingApril 2, 2024 | seekingalpha.comAyala Pharmaceuticals Announces Completion of Sale of AL102 to ImmunomeMarch 26, 2024 | globenewswire.comSee More Headlines ADXS Stock Analysis - Frequently Asked Questions How have ADXS shares performed this year? Ayala Pharmaceuticals' stock was trading at $0.0270 at the start of the year. Since then, ADXS shares have increased by 308.5% and is now trading at $0.1103. View the best growth stocks for 2025 here. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) announced its quarterly earnings data on Thursday, September, 9th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The business had revenue of $0.25 million for the quarter. How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Acasti Pharma (ACST), Bristol-Myers Squibb (BMY) and Company Calendar Last Earnings9/09/2021Today5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADXS CIK1100397 Webwww.ayalapharma.com Phone609-452-9813Fax609-452-9818Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.24 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value($2.06) per share Price / Book-0.05Miscellaneous Outstanding Shares42,633,000Free Float42,364,000Market Cap$4.70 million OptionableNot Optionable Beta1.25 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:ADXS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.